Back to News
Market Impact: 0.35
MHRA approves Pharming's Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K.
Source: globenewswire.com
Healthcare & BiotechRegulation & Legislation
The U.K. MHRA approved Pharming’s Joenja® (leniolisib) as the first treatment specifically for children with APDS. The approval extends Joenja’s existing U.K. indication; the article provides no sales, patient-population or market-reaction figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
PHAR0.85
More News
- Tech stock rout, driven by US AI fears, continues in Asian trading
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Paraguay’s Santiago Pena under arrest, new president Pedro Alliana sworn in
- EU tells TikTok to fix ‘harmful’ For You feed, threatens fines
- OpenAI to press ahead with data-center expansion despite midterm sweep, CFO tells CNBC